Clinical Trials Logo

Antidepressive Agents clinical trials

View clinical trials related to Antidepressive Agents.

Filter by:

NCT ID: NCT03195231 Not yet recruiting - Clinical trials for Antidepressive Agents

Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease

Start date: June 25, 2017
Phase: Phase 4
Study type: Interventional

Depression is one of the most important nonmotor features of idiopathic PD(Parkinson's disease )which may not just interfere with the motor symptoms of PD but can also cause immense personal suffering as well as decreased quality of life with increased disability and caregiver burden. However,there is little hard evidence to guide clinical treatment. Although some newer dopamine agonists also have antidepressive effect, the use of tricyclic or nontricyclic antidepressants is frequently required.However, the side-effects of these agents may also worsen some preexisting nonmotor problems in PD. Wuling powder is a Chinese medicine which is made by cultivating Xylariasp mycelium using submerged fermentation technology. Xylariasp is the fungus sclerotia which grow in termite nests. Wuling powder is mainly used to soothe nerves and anti-insomnia in clinical. The antidepressant effect of Wuling powder has been confirmed in clinical, but not in the patients of Parkinson`s disease. Therefore, the investigators design a randomized, double-blind, placebo-controlled study to evaluate the antidepressant effect of Wuling powder in PD patients and its underlying mechanism.

NCT ID: NCT02263872 Completed - Depressive Disorder Clinical Trials

Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial

Start date: October 2014
Phase: Phase 4
Study type: Interventional

In this double blind randomised controlled pilot trial the investigators aim to determine the efficacy of minocycline as an adjunct to treatment as usual in patients with major depressive disorder. The investigators hypothesize that the multiple neuroprotective effects of minocycline will lead to an improvement in depressive symptoms in participants that were given minocycline plus treatment as usual

NCT ID: NCT01204086 Recruiting - Clinical trials for Major Depressive Disorder

Pharmacogenomics Studies of Antidepressants

Start date: March 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to establish the clinical effectiveness of antidepressants by pharmacogenomic approach, and to determine the levels of inflammatory factors between the baseline and the end point of the study in Taiwanese major depressive disorder (MDD) patients.